The Beneluxa Initiative

🌟 General Assembly & Steering Committee Meeting of the Beneluxa initiative On 9 December 2024, the annual General Assembly of the Beneluxa Initiative took place in Luxembourg. The day involved information on ongoing activities, workshops on various topics, such as international collaboration or the EU HTA regulation, and discussion sessions. During the General Assembly, the official handover of the Chair and Vice Chair of Beneluxa took place. We thank the Netherlands for their outstanding work as the previous chair and congratulate Ireland and Luxembourg to take over the role as the new chair and the Vice chair respectively.   The following day on 10 December 2024, the Steering Committee of the Beneluxa Initiative met. Key topics of discussion included: 🔹 Insights in national policies and politics 🔹 Updates from the Domain Task Forces (DTFs) 🔹 Strategic planning for the future activities of the Beneluxa Initiative. 🔹 Exploring potential further collaborations.   In the course of the meetings, the Minister of Health and Social Security, Martine Deprez, honored us with her visit. We thank the Ministry of Health and Social Security Luxembourg for hosting both meetings in Luxembourg. Read more: https://lnkd.in/dFYfMnJS

After a successful joint assessment of the gene therapy Hemgenix® by Belgium and the Netherlands, both countries decided together that the best course of action for this specific case is to proceed with individual negotiations. While joint negotiations remain the preferred approach for both governments after a joint Health Technology Assessment, and alignment was achieved on how to establish the willingness to pay, differences in healthcare systems— in this case particularly in how the cost of the current standard of care is structured—led to a different outcome of the recommendation for reimbursement. 🔎 Please find the complete news item on our website: https://lnkd.in/dMUNR2-r

Another Joint #HTA has been completed by the #Beneluxa Initiative: The gene therapy #Hemgenix® was assessed by #Belgium and the #Netherlands. Cross-border consultations resulted in a scientific and budget impact analysis report, approved in both countries where the company submitted the dossier. The full report can be consulted on the public website of Zorginstituut Nederland here: https://lnkd.in/dViFnkPu More information on the Beneluxa website: https://lnkd.in/deKhFeaQ

🌟 Steering Committee Meeting of the Beneluxa initiative On June 25, 2024, the Steering Committee of the Beneluxa Initiative met in Brussels, Belgium. Key topics of discussion included: 🔹 Insights in national policies and politics 🔹 Updates from the Domain Task Forces (DTFs) 🔹 Insights and reflections on the initiative’s activities, particularly focusing on experiences with joint negotiations. 🔹 Strategic planning for the future activities of the Beneluxa Initiative. 🔹 Exploring potential new collaborations.   We thank RIZIV-INAMI for hosting this year’s first Steering Committee Meeting. Read also here: https://lnkd.in/dqwb3mmF

🌐 Beneluxa Webinar on Alzheimer’s Disease: Exploring New Horizons in Treatment On 6th June 2024, the Beneluxa Initiative held a #Beneluxa scoping webinar on #Alzheimer's disease. 30 experts, representing prescribers, public payers and patient organizations, of the five Beneluxa countries joined to discuss the evolving landscape of Alzheimer's treatment and to share their views on the potential benefits of the new medicines and implications for the organisation of care. The webinar hosted by the Dutch National Health Care Institute (Zorginstituut Nederland) marks a significant step in fostering international #collaboration and understanding the potential impacts of new treatments. 👉 More information: https://lnkd.in/dc7GehEa

🌐 Beneluxa Webinar on Alzheimer’s Disease: Exploring New Horizons in Treatment On 6th June 2024, the Beneluxa Initiative held a #Beneluxa scoping webinar on #Alzheimer's disease. 30 experts, representing prescribers, public payers and patient organizations, of the five Beneluxa countries joined to discuss the evolving landscape of Alzheimer's treatment and to share their views on the potential benefits of the new medicines and implications for the organisation of care. The webinar hosted by the Dutch National Health Care Institute (Zorginstituut Nederland) marks a significant step in fostering international #collaboration and understanding the potential impacts of new treatments. 👉 More information: https://lnkd.in/dc7GehEa

The #Beneluxa Initiative announces successful conclusion of #Libmeldy price negotiations, directly benefiting patients in three countries. As members of the Beneluxa Initiative, Ireland, Belgium and the Netherlands, have successfully concluded joint pricing negotiations for Libmeldy, a treatment designed for Metachromatic Leukodystrophy (MLD), having arrived at a mutually agreeable pricing arrangement with the manufacturer Orchard Therapeutics.   #MLD is a rare disease affecting an estimated 1 in 40,000 – 160,000 people. Its effects are devastating to those suffering with it and their families. Children with MLD will directly benefit from this agreement as Libmeldy will become available for reimbursement in the three countries.   The negotiations were carried out based on a joint Health Technology Assessment (HTA) procedure involving the three countries, showcasing the effectiveness of a unified approach in ensuring equitable #access to innovative therapies. The outcome of successive negotiations with the manufacturer has shown that #collaboration through the Beneluxa Initiative can support positive outcomes for countries and, in particular, for patient access to the latest medications. Access to Libmeldy through this multi-country agreement is a testament to the collaborative spirit driving the Beneluxa Initiative.   Read more on statements of the Ministers on our website: https://lnkd.in/d_nh5ZfY